Heron Therapeutics Reports Preliminary Q4 and Full-Year 2025 Revenue, Driven by Strong ZYNRELEF Growth
summarizeSummary
Heron Therapeutics released preliminary Q4 and full-year 2025 revenue figures, highlighting strong growth in its Acute Care franchise, particularly ZYNRELEF, which saw a 35% quarter-over-quarter increase.
check_boxKey Events
-
Preliminary Q4 and Full-Year 2025 Revenue Announced
Heron Therapeutics reported preliminary, unaudited net revenue of approximately $40.5 million for Q4 2025 and $154.9 million for the full year 2025.
-
ZYNRELEF Drives Q4 Growth
ZYNRELEF net revenue reached approximately $12.5 million in Q4 2025, representing the largest quarter-over-quarter increase within the portfolio, up approximately 35% from Q3 2025.
-
Acute Care Franchise Momentum
The company noted encouraging growth in its Acute Care franchise, which includes ZYNRELEF and APONVIE, with APONVIE contributing approximately $3.8 million in Q4 net revenue.
auto_awesomeAnalysis
Heron Therapeutics announced preliminary, unaudited financial results for Q4 and full-year 2025, indicating solid revenue performance. The reported full-year revenue of approximately $154.9 million and Q4 revenue of $40.5 million provide an early look at the company's financial health. Notably, ZYNRELEF, a key product in the Acute Care franchise, showed significant quarter-over-quarter growth of approximately 35% in Q4 2025, contributing $12.5 million. This strong performance in the Acute Care segment, also including APONVIE, suggests positive commercial momentum. While these results are preliminary and unaudited, they offer an encouraging signal regarding the company's product adoption and revenue trajectory.
At the time of this filing, HRTX was trading at $1.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $271.4M. The 52-week trading range was $1.00 to $2.68. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.